Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
IPO Year:
Exchange: NYSE
Website: drreddys.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/11/2024 | Buy → Underperform | Jefferies | |
8/29/2023 | Buy → Hold | HSBC Securities | |
5/18/2023 | Outperform → Mkt Perform | Bernstein | |
3/17/2023 | Neutral → Buy | BofA Securities | |
1/30/2023 | Underweight | JP Morgan | |
11/14/2022 | Neutral → Underperform | Credit Suisse | |
1/3/2022 | Neutral | BofA Securities | |
11/1/2021 | $78.00 → $80.00 | Overweight | Barclays |
7/27/2021 | Outperform → Neutral | Credit Suisse |
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)
SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)
SC 13G/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY24 FY24 Revenues ₹ 70,830 Mn [Up: 12% YoY; Down: 2% QoQ]^ ₹ 279,164 Mn [Up: 14% YoY]^ Gross Margin 58.6% [Q4FY23: 57.2%; Q3FY24: 58.5%] 58.6% [FY23: 56.7%] SG&A Expenses ₹ 20,476 Mn [Up: 14% YoY; 1% QoQ] ₹ 77,201 Mn [Up: 13%
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced that it has acquired MenoLabs® business, a leading women's health and dietary supplement branded portfolio from Amyris, Inc. ("Amyris") in Amyris' Chapter 11 sales process. Dr. Reddy's acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause. Brands include MenoFit™ and MenoGlow™ probiotics, Happy Fiber™ and Well Rested™ dietary supplements, Athena's Shield™ menopause support supplement, and Goodn
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter ended Sep 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Revenues Rs. 68,802 Mn [Up: 9% YoY; Up: 2% QoQ] Gross Margin 58.7% [Q2 FY23: 59.1%; Q1 FY24: 58.7%] SG&A Expenses Rs. 18,795 Mn [Up: 13% YoY; 6% QoQ] R&D Expenses Rs. 5,447 Mn[7.9% of Revenues] EBITDA Rs. 21,813 Mn [31.7% of Revenues] Profit before Tax Rs. 19,134 Mn [Up: 19% YoY; Up: 4% QoQ]
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter ended June 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Revenues Rs. 67,384 Mn [Up: 29%* YoY; Up: 7%* QoQ] Gross Margin 58.7% [Q1 FY23: 49.9%; Q4 FY23: 57.2%] SG&A Expenses Rs. 17,702 Mn [Up: 14% YoY; Down: 2% QoQ] R&D Expenses Rs. 4,984 Mn [7.4% of Revenue
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005650/en/Q4 FY23 Sales Mix (Graphic: Business Wire) Q4 Performance Summary FY23 Performance Summary Rs. 6,297 Cr Rs. 24,588 Cr Revenue Revenue [Up: 16% YoY; Down 7% QoQ] [Up: 15% YoY] 57.2% 56.7%
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")) today announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois based-Eton Pharmaceuticals, Inc. (NASDAQ:ETON). The portfolio includes the Biorphen® (phenylephrine hydrocholoride) Injection and Rezipres® (ephedrine hydrochloride) Injection NDAs with nine separate combinations of strengths and presentations and one first-to-file approved ANDA for Cysteine Hydrochloride for the U.S. One strength each of Biorphen® and Rezipres® are currently commercially available in the U.S. The acquisit
CRANFORD, N.J., Sept. 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's") (NYSE:RDY) to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. E7777, an engineered IL-2-diphtheria toxin fusion protein, is an improved formulation of oncology agent, ONTAK®, which was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with persist
On Wednesday, Haleon plc (NYSE:HLN) agreed to sell its nicotine replacement therapy business outside of the U.S. to Dr. Reddy's Laboratories SA, a wholly owned subsidiary of Dr. Reddy's Laboratories Limited (NYSE:RDY) for 500 million pounds (around $632 million). The nicotine replacement therapy (NRT) portfolio consists of brands such as Nicotinell, Nicabate, Habitrol, and Thrive, which are available in gum, lozenge, and patch forms across over 30 markets. The 500 million pound consideration is structured as an upfront cash payment of 458 million pounds, with a further up to 42 million pounds deferred performance-based consideration payable during 2025 and H1 2026. The transaction
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United StatesAcquisition seen as ideal anchor to continue to build the company's global consumer healthcare OTC businessIn recent years, Dr. Reddy's has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé IndiaDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), a global pharmaceutical company, today announced that its subsidiary Dr. Re
- Reuters
Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $80 to $81.
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr
Malaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential partnership is a step towards this cause This potential partnership aims to bring together Kainomyx's expertise in novel drug discovery, Aurigene's capability to conduct integrated drug discovery and development, and Dr. Reddy's ability to commercialize products in low and middle-income countries, in addition to the US and Europe It is a testament to the commitment of involved parties towards promoting global public health and Dr. Reddy's goal of reaching 1.5 billion pat
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the launch of its proposed biosimilar Rituximab candidate DRL_RI (ITUXREDI®) in European markets. Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance and drug product manufacturing facility located in Hyderabad, India. As part of the established approval process, the CHMP positive opinion will now be reviewed by the European Commission (EC),
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company's global consumer healthcare OTC business In recent years, Dr. Reddy's has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé India Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), a global pharmaceutical company, today announced that its sub
Aurigene Pharmaceutical Services Limited ("Aurigene"), a Dr. Reddy's Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical requirements. The process and analytical development laboratories are now operational while the commissioning of manufacturing capacity will be completed later in 2024. The state-of-the-art facility is equipped with best-in-class equipment and control systems, supported by a
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr
Dr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's")), today announced that the companies have entered into a license and supply agreement for the c
Dr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product HYDERABAD, India and REYKJAVIK, Iceland, May 21, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's")), today announced
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY24 FY24 Revenues ₹ 70,830 Mn [Up: 12% YoY; Down: 2% QoQ]^ ₹ 279,164 Mn [Up: 14% YoY]^ Gross Margin 58.6% [Q4FY23: 57.2%; Q3FY24: 58.5%] 58.6% [FY23: 56.7%] SG&A Expenses ₹ 20,476 Mn [Up: 14% YoY; 1% QoQ] ₹ 77,201 Mn [Up: 13%
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's Doxycycline Capsules, 40 mg*, are supplied in bottle counts of 30. Please click here to see the full prescribing information - https://www.drreddys.com/pil/doxycycline-capsules.pdf. *Each capsule contains: 26 mg immediate-release pellets and 14 mg delayed-release pellets equivalent to 40 mg of anhydro
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat critically ill patients, announced that it has entered into a license agreement with Dr. Reddy's Laboratories Limited ("Dr. Reddy's"), a global pharmaceutical company, to commercialize a first-in-c
Jefferies downgraded Dr. Reddy's from Buy to Underperform
HSBC Securities downgraded Dr. Reddy's from Buy to Hold
Bernstein downgraded Dr. Reddy's from Outperform to Mkt Perform
BofA Securities upgraded Dr. Reddy's from Neutral to Buy
JP Morgan initiated coverage of Dr. Reddy's with a rating of Underweight
Credit Suisse downgraded Dr. Reddy's from Neutral to Underperform
BofA Securities resumed coverage of Dr. Reddy's with a rating of Neutral
Barclays reiterated coverage of Dr Reddy's Laboratories with a rating of Overweight and set a new price target of $80.00 from $78.00 previously
Credit Suisse downgraded Dr. Reddy's from Outperform to Neutral
Investec upgraded Dr. Reddy's Laboratories from Hold to Buy